Group 1 - Liu Pharmaceutical Group plans to repurchase shares worth between 100 million and 200 million yuan, with a maximum repurchase price of 25.70 yuan per share [1] - Dongshan Precision intends to invest up to 1 billion USD to build a high-end printed circuit board project to meet the long-term demand for high-end printed circuit boards in emerging scenarios such as AI [1] - Bomaike reported a net profit of 12.39 million yuan for the first half of the year, a year-on-year decline of 80.42% [2] Group 2 - Western Mining achieved a net profit of 1.869 billion yuan in the first half of the year, a year-on-year increase of 15% [2] - Fuliwang expects a net loss of approximately 17 million yuan for the first half of the year, a decrease of 137.12% compared to the same period last year [2] - Digital Certification anticipates a net loss of between 80 million and 96 million yuan for the first half of the year, compared to a loss of 29.25 million yuan in the same period last year [3] Group 3 - Shanghai Construction reported a net profit of 710 million yuan for the first half of the year, a year-on-year decrease of 14.04% [5] - Funneng Co. achieved a net profit of 1.337 billion yuan in the first half of the year, a year-on-year increase of 12.48% [6] - Tengda Construction's total contract amount for the first half of the year decreased by 17.55% year-on-year [7] Group 4 - Fudan Fuhua decided to terminate the public transfer of a 28% stake in a subsidiary due to the lack of a deposit from potential buyers [9] - Fulei Ant's subsidiary has decided to cease operations due to intense competition in the photovoltaic industry and ongoing losses [11] - Dongfang Ocean's subsidiary received a medical device registration certificate for a folic acid testing kit [14] Group 5 - Huayu Pharmaceutical's subsidiary received overseas listing approvals for several products [16] - Feima International received a performance commitment compensation of 437 million yuan from its controlling shareholder [16] - Guangshen Railway signed a cooperation agreement for the Guangzhou East Station renovation project with a total investment of approximately 16.66 billion yuan [16] Group 6 - Anhui Construction won the bid for the S68 Jingde to Jixi Expressway project with an estimated total investment of 5.7 billion yuan [18] - China Communications Construction Company signed new contracts worth 991.054 billion yuan in the first half of the year, a year-on-year increase of 3.14% [19] - Kehui Co. plans to use up to 70 million yuan of idle funds for cash management [22] Group 7 - Biological Shares' subsidiary received a clinical trial approval for a cat mRNA vaccine, the first of its kind in China [23] - Ruipu Biological received a clinical trial approval for a pig mRNA vaccine, which is the first economic animal mRNA vaccine in China [24] - Nanjing New Hundred's major assets were judicially frozen due to liquidity debt crisis faced by its controlling shareholder [27] Group 8 - Changshu Bank plans to merge three village banks and establish branches, pending shareholder approval [28] - Yong'an Pharmaceutical plans to reduce its holdings by up to 2.6323 million shares [29] - Zhujiang Co. received approval from the Shanghai Stock Exchange for a stock issuance to specific targets [31] Group 9 - Sanyangma's subsidiary signed a 120 million yuan procurement contract for sensor products [33] - Jintou City Development plans to purchase a villa property for approximately 7.1854 million yuan [35] - Yuanli Co. intends to acquire 100% of Tongsheng Co. through a combination of cash and stock issuance [36] Group 10 - Xin'an Century's controlling shareholder plans to reduce holdings by up to 2.22% of the company's shares [36] - Fute Technology plans to raise up to 528 million yuan through a private placement for various projects [36] - Helen Piano's actual controller is set to change, with stock resuming trading [37] Group 11 - Weiergao expects a net profit increase of 12.55% to 30.87% for the first half of the year [38] - Saiwei Microelectronics plans to transfer up to 18% of its shares through an agreement [40] - Yongli Co. intends to acquire a 22.75% stake in a subsidiary [42] Group 12 - ST Xiachuang plans to publicly transfer a 20% stake in Guangdong Yuweiji [43] - Dema Technology's shareholders plan to transfer 778.84 million shares through an inquiry [45] - Zhongshi Technology's shareholders plan to reduce holdings by up to 2.86% of the company's shares [46] Group 13 - Wufang Optoelectronics' controlling shareholder plans to reduce holdings by up to 0.93% of the company's shares [48] - Fusenmei's chairman has been detained, temporarily unable to fulfill his duties [49] - Reliable Co.'s shareholders plan to reduce holdings by a total of up to 2.63% of the company's shares [51] Group 14 - Gao Neng Environment plans to repurchase shares worth between 100 million and 150 million yuan [53]

证券代码：688553 证券简称：汇宇制药 公告编号：2025-055 四川汇宇制药股份有限公司 股东名称 黄乾益 股东身份 控股股东、实控人及一致行动人 □是 √否 一、减持主体减持前基本情况 | | 直接持股 5%以上股东 | √是 | □否 | | --- | --- | --- | --- | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：不适用 | | | | 持股数量 | 27,219,439股 | | | | 持股比例 | 6.426% | | | | 当前持股股份来源 | IPO 前取得：27,219,439股 | | | 持股 5%以上股东减持股份计划时间届满暨减持股份 结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露之日，四川汇宇制药股份有限公司(以下简称"公司")股东 黄乾益持有公司股份数量为 27,219,439 股，占公司总股本的 6.426%；上述股份 来源于公司首次公开发行前取得的股份，且已于 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-056 公司唑来膦酸注射液研发成功后已进行了多国注册申报，分别已在中国、英 国、法国、葡萄牙、荷兰、西班牙、意大利、德国等 15 个国家获得上市许可。 截至目前，公司已分别在越南、巴基斯坦等 5 个国家提交注册申请。 （二）注射用赛替派 四川汇宇制药股份有限公司 关于自愿披露公司产品获得境外上市许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）子公司 Seacross Pharma (Europe) Ltd.近期收到德国国家药品和保健品安全局和沙特阿拉伯健康产品监管 局分别核准签发的公司产品唑来磷酸注射液、注射用赛替派、丙戊酸钠注射用浓 溶液和注射用盐酸苯达莫司汀的上市许可。现将相关情况公告如下： 二、药品的其他相关情况 （一）唑来膦酸注射液 唑来膦酸注射液主要用于治疗绝经后妇女以及成年男性的骨质疏松症，治疗 绝经后妇女以及成年男性长期糖皮质激素治疗诱发的骨质疏松症，以及成人 Paget's 骨病（变形性骨 ...

Core Insights - The company’s subsidiary, Seacross Pharma Ltd., has recently obtained marketing approvals from the German Federal Institute for Drugs and Medical Devices and the Saudi Food and Drug Authority for several products, including Zoledronic Acid Injection, Injection for Cetuximab, Sodium Valproate Injection Concentrate, and Bendamustine Hydrochloride Injection [1] Group 1 - The approvals will help the company enhance its international product pipeline, improve brand image, and expand the breadth and depth of its international business [1] - The company has prepared for the market launch and sales of these products [1] - Future revenue generation remains uncertain due to market competition and other factors [1]

Market Performance - The recombinant protein concept increased by 2.92%, ranking 7th among concept sectors, with 43 stocks rising, including Chengdu Xian Dao and Mai Wei Bio reaching a 20% limit up [1] - Leading gainers included Shen Zhou Cell, Hai Te Bio, and Ke Xing Pharmaceutical, with increases of 15.40%, 11.93%, and 10.14% respectively [1] - Decliners included ST Wei Ming, *ST Su Wu, and Lizu Group, with decreases of 5.01%, 4.81%, and 0.49% respectively [1] Capital Flow - The recombinant protein sector saw a net inflow of 188 million yuan, with 17 stocks receiving net inflows, and 5 stocks exceeding 30 million yuan in net inflow [1] - Shen Zhou Cell led with a net inflow of 217 million yuan, followed by Chengdu Xian Dao, Mai Wei Bio, and Hui Yu Pharmaceutical with net inflows of 126 million yuan, 96.87 million yuan, and 45.41 million yuan respectively [1] Capital Inflow Ratios - Leading stocks in capital inflow ratios included Shen Zhou Cell, Chengdu Xian Dao, and Cheng Da Bio, with net inflow ratios of 16.25%, 12.33%, and 10.79% respectively [2] - The top stocks in the recombinant protein concept based on capital flow included Shen Zhou Cell, Chengdu Xian Dao, and Mai Wei Bio, with respective daily turnover rates of 3.70%, 12.33%, and 17.80% [2]

Core Points - Sichuan Huiyu Pharmaceutical Co., Ltd. has completed the investment project "High-end Green Pharmaceutical Industry Extension Project" using the raised funds and is now proposing to conclude this project [1][4] - The total amount raised from the public offering was 2,472.132 million RMB, with a net amount after deducting issuance costs [1] - The company has utilized 1,907.315 million RMB for projects related to its main business, with an additional 453.3598 million RMB from over-raised funds [2][4] Fundraising and Investment Project Details - The company issued 63,600,000 shares at a price of 38.87 RMB per share, leading to a total fundraising amount of 2,472.132 million RMB [1] - The total investment amount for the main business-related projects was 1,907.315 million RMB, while the total amount of over-raised funds was 453.3598 million RMB [2] - As of the announcement date, the remaining unused amount of over-raised funds was 44.46 RMB [2] Project Completion and Financial Summary - The "High-end Green Pharmaceutical Industry Extension Project" has completed construction, with some production lines already in trial production, meeting the conditions for project conclusion [4] - The total investment for the project was 315.61 million RMB, with 288.61 million RMB already invested and a remaining balance of 17.60753 million RMB after accounting for interest income [4] - The supervisory board has approved the conclusion of the project, confirming that it aligns with the interests of the company and its shareholders [4]

一、募集资金基本情况 证券代码：688553 证券简称：汇宇制药 公告编号：2025-054 四川汇宇制药股份有限公司 关于超募资金投资项目结项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"汇宇制药"或"公司"）于 2025 年 7 月 15 日召开第二届董事会第十六次会议和第二届监事会第十六次会议，审 议通过了《关于超募资金投资项目结项的议案》，同意对公司超募资金投资项目 "高端绿色药物产业延链项目"予以结项。现将具体情况公告如下： 经上海证券交易所科创板上市委员会 2021 年 5 月 26 日审核同意，并经中国 证券监督管理委员会于 2021 年 8 月 3 日《关于同意四川汇宇制药股份有限公司 首次公开发行股票注册的批复》（证监许可〔2021〕2596 号）同意注册，汇宇 制药向社会公开发行人民币普通股（A 股）股票 63,600,000 股，发行价格 38.87 元/股，本次发行的募集资金总额为 247,213.20 万元，扣除相关发行费用人民币 11,145.72 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-053 四川汇宇制药股份有限公司 监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 四川汇宇制药股份有限公司（以下简称"公司"或"汇宇制药"）第二届监事会 第十六次会议于 2025 年 7 月 10 日以电子邮件方式发出通知，并于 2025 年 7 月 15 日以通讯表决方式召开。本次会议由公司监事会主席邓玲女士召集并主持， 应出席监事 3 人，实际出席监事 3 人。全体监事认可本次会议的通知时间、议案 内容等事项，本次监事会的召集和召开程序符合《中华人民共和国公司法》《中 华人民共和国证券法》等法律法规及《公司章程》的相关规定，会议决议合法有 效。 二、监事会会议审议情况 1、审议通过《关于超募资金投资项目结项的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）上披露的 《汇宇制药关于超募资金投资项目结项的公告》（公告编号：2025-054） ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-052 四川汇宇制药股份有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 四川汇宇制药股份有限公司（以下简称"公司""汇宇制药"）第二届董事会 第十六次会议于 2025 年 7 月 15 日以通讯表决方式召开。会议通知和会议资料已 于 2025 年 7 月 10 日以电子邮件方式发出。本次会议由董事长丁兆先生主持，会 议应出席董事 8 人，实际出席董事 8 人，相关监事及高管列席。全体董事一致同 意并认可本次会议的通知和召开时间、议案内容等事项，本次董事会会议的召集 和召开程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的 规定，作出的决议合法、有效。 二、董事会会议审议情况 表决结果：8 票赞成；0 票弃权；0 票反对。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《汇 宇制药关于超募资金投资项目结项的公告》（公告编号：2025-054）。 特此公告。 四川汇宇制 ...

Market Overview - The Sci-Tech Innovation Board (科创板) index fell by 0.89%, closing at 983.11 points, with a total trading volume of 2.85 billion shares and a turnover of 94.90 billion yuan, resulting in a weighted average turnover rate of 1.59% [1] - Among the tradable stocks on the Sci-Tech Innovation Board, 180 stocks closed higher, with 5 stocks rising over 10%, including Aowei New Materials, Haosen Intelligent, and Qinchuan Internet of Things, which hit the daily limit [1] Trading Activity - The distribution of turnover rates shows that 2 stocks had turnover rates exceeding 20%, 11 stocks had rates between 10% and 20%, and 36 stocks had rates between 5% and 10% [1] - C Yitang, a newly listed stock, had the highest turnover rate at 50.54%, closing down by 9.66% with a trading volume of 2.20 billion yuan and a net outflow of 134 million yuan [1][2] - Other notable stocks with high turnover rates include Jinchengzi, which closed down by 5.60% with a turnover rate of 25.85%, and Xinyuren, Sikan Technology, and Meidixi, with turnover rates of 18.75%, 16.84%, and 16.24% respectively [1][2] Sector Performance - In the high turnover rate stocks, the pharmaceutical and biological sector had the most representation, with 10 stocks listed, followed by the power equipment and machinery sectors, each with 8 stocks [2] - Among the high turnover stocks, 23 stocks saw an increase, with Haosen Intelligent, Qinchuan Internet of Things, and Meidixi leading with gains of 20.02%, 19.98%, and 13.36% respectively [2] Fund Flow - In terms of fund flow, 22 stocks experienced net inflows, with the highest inflows seen in Huyou Pharmaceutical, Jinchengzi, and Jiayuan Technology, with net inflows of 59.84 million yuan, 40.28 million yuan, and 38.97 million yuan respectively [2] - Conversely, C Yitang, Zhengfan Technology, and Weice Technology had the largest net outflows, with outflows of 134 million yuan, 62.06 million yuan, and 61.24 million yuan respectively [2] Leverage Fund Movements - Recent data indicates that 28 stocks have received net purchases from leveraged funds, with C Yitang, Huyou Pharmaceutical, and Rongchang Bio having the largest increases in financing balances of 208 million yuan, 114 million yuan, and 6.05 million yuan respectively [3]